Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 500 participants.
Also called NCT07697833
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 500 participants
- Registry
-
NCT07697833
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07697833. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-15 (anticipated); primary completion 2027-05-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure Patients
- Acronym
- VERICIGUAT
- Intervention (Drug)
- Vericiguat tablet
- Intervention (Drug)
- Placebo
- Lead sponsor
- National Institute of Cardiovascular Diseases, Pakistan
- Collaborator
- Horizon Pharmaceuticals
Record details
- Record id
cardio:ct-nct07697833- Content hash
cc14605c33811dc0d1a24cea0812c0f50f8265cff992ab994e874d269d77190f